Sphingosine kinase as a target for anti-cancer therapy

鞘氨醇激酶作为抗癌治疗的靶点

• 批准号: nhmrc : 1042589
• 负责人: Prof Stuart Pitson
• 金额: $ 50.1万
• 依托单位: University of South Australia
• 依托单位国家: 澳大利亚
• 项目类别: Research Fellowships
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/sphingosine-kinase-target-cancer-therapy/111491
• 关键词: Sphingosine; kinase; target; anti; cancer

Sphingosine kinase is a protein involved in the development and progression of numerous types of solid tumors and leukaemias. We have recently made a major break-through by identifing how the cancer-inducing activity of sphingosine kinase is controlled. In this study we will target these control mechanisms to develop potential new anti-cancer therapies.

鞘氨醇激酶是一种参与多种类型的实体瘤和白血病的发展和进展的蛋白质。最近，我们通过确定鞘氨醇激酶的致癌活性是如何控制的，取得了重大突破。在这项研究中，我们将针对这些控制机制来开发潜在的新抗癌疗法。